CD34 and acute myeloid leukemia: These include the recent development of a transplantable human KMT2A/MLLT3 AML xenograft model, using human UCB CD34+ HSPCs and CRISPR/Cas9 genome editing technologies, which also reported that the developmental age and the genetic background of the human CD34+ HSPCs, as well as the microenvironmental niche in surrogate murine models of hematopoiesis influenced AML progression [211].